It is made available under a CC-BY-NC-ND 4.0 International license .

1 Third vaccine doses could have indirectly averted >100,000 deaths in the USA by reducing

- 2 transmission of the SARS-CoV-2 Delta variant
- 3 Billy J. Gardner*, A. Marm Kilpatrick*
- 4
- 5 Department of Ecology and Evolutionary Biology, University of California, Santa Cruz, Santa
- 6 Cruz, California, 95064 USA
- 7 **To whom correspondence should be addressed: <u>wjgytc14@gmail.com</u>; <u>akilpatr@ucsc.edu</u>*
- 8 A. Marm Kilpatrick
- 9 130 McAllister Way
- 10 EE Biology/CBB
- 11 University of California
- 12 Santa Cruz, CA 95060
- 13 Preprint Server: medRxiv: https://www.medrxiv.org/content/10.1101/2021.10.25.21265500
- 14 Classification Biological Sciences: Applied Biological Sciences
- 15 Keywords COVID-19; vaccine effectiveness, surrogates of protection, vaccination; waning
- 16 immunity; herd immunity, modeling

It is made available under a CC-BY-NC-ND 4.0 International license .

18 Abstract

19 Vaccination programs often focus on direct protection of individuals against disease and discount 20 reductions in transmission, which can result in preventable disease and death. Initial clinical 21 trials for most COVID-19 vaccines only measured direct protection, and dosing and vaccine 22 selection decisions have, so far, ignored effects on transmission. Here we provide an empirical 23 framework for incorporating indirect effects of COVID-19 vaccination on transmission in a 24 continuous dynamic immune landscape. For the first time, we quantified relationships between 25 neutralizing antibody titers and vaccine effectiveness for both susceptibility (VEs) and 26 infectiousness (VEI) and quantified changes in VE with waning and boosting of immunity. We 27 used these relationships to quantify the impact that additional doses of mRNA vaccines 28 (BNT162b2 and mRNA-1273) could have had in reducing transmission and deaths caused by the 29 deadliest SARS-CoV-2 variant, Delta, in Autumn 2021. Neutralizing antibodies waned 8-fold in 30 2021 over the six months following initial vaccination with mRNA vaccines, which reduced VEs 31 33-38% (from 75-81% to 47-54%) and VE₁62-65% (from 47-57% to 16-22%) against the Delta 32 variant. Third doses increased neutralizing antibody titers 13-26-fold, which more than restored 33 VE and reduced the relative risk of transmission 7-10-fold. Administering third doses by 34 September 1, 2021 could have reduced the effective reproductive number Rt by 19%, stopped 35 surges in transmission in many populations, and averted an estimated 111,491 deaths in the 36 United States. Vaccination programs that incorporate effects on transmission in trial design, 37 vaccination frequency, and vaccine choice are needed to address current and future public health challenges. 38

39

It is made available under a CC-BY-NC-ND 4.0 International license .

41 Significance

42	Vaccination programs for many diseases often focus primarily on people at risk of severe disease
43	and sometimes discount indirect reductions in transmission. We developed a framework for
44	estimating the effects of vaccination on transmission and used it to estimate the number of
45	COVID-19 deaths that could have been averted by deploying third doses during the Delta variant
46	surge to reduce transmission. We show that immunity against transmission had waned
47	significantly in late 2021. However, widespread deployment of third doses could have restored
48	protection, stopped surges of the Delta variant, and prevented more than 100,000 deaths in the
49	United States. Vaccination programs should incorporate effects on transmission in initial trial
50	design, vaccination frequency, and vaccine selection to address public health challenges.

It is made available under a CC-BY-NC-ND 4.0 International license .

52 Introduction

53 Vaccination is the most effective tool for reducing disease, hospitalizations, and deaths for many infectious diseases ^{1–5}. Core components of vaccination programs include how to 54 55 allocate vaccine doses within and between individuals, when to recommend new doses and, 56 when multiple vaccines are available, which vaccines to recommend. In making these decisions 57 and developing new vaccines, public health agencies often focus on the direct impact of vaccines in reducing disease in vaccinated individuals ^{6,7}. For example, the United States Food and Drug 58 59 Administration guidelines for randomized control trials for COVID-19 vaccines did not include any criteria regarding protection against infection or reductions in infectiousness⁸, and, as a 60 61 result, these weren't measured in the US trials for mRNA vaccines made by Pfizer-BioNTech 62 and Moderna. Similarly, vaccines are often only recommended for subsets of the population at high risk disease severity⁹, despite the fact that in many cases, such as pneumococcal disease, 63 vaccines have been shown to reduce transmission ¹⁰. 64

65 Many vaccines can have population-wide benefits by reducing transmission either by 66 reducing susceptibility or reducing infectiousness (i.e. transmission from breakthrough infections), or both, which indirectly protects additional individuals ¹¹. In these cases, 67 68 vaccinating individuals who are not at risk of severe disease can reduce severe disease through reductions in transmission ¹². Deploying vaccines to reduce transmission can increase health 69 70 equity by reducing infection in individuals that lack access to health care, including vaccination, 71 which is a key global challenge ¹³. However, determining whether the benefits of deploying 72 vaccines to reduce transmission is warranted requires estimating vaccine effectiveness (VE) for transmission and the potential number of deaths averted for a specific population, which, in turn, 73 74 depends on the dynamic levels of population immunity for the pathogen in question.

It is made available under a CC-BY-NC-ND 4.0 International license .

75 The emergence of the Delta variant (B.1.617.2) of SARS-CoV-2 in 2021 illustrates the potential benefit of using vaccination to reduce transmission. The Delta variant caused a surge of 76 deaths globally, even in populations with high initial two-dose vaccination coverage ¹⁴. This was 77 due, in part, to the higher infectiousness and severity of this virus variant ^{15,16}, partial immune 78 79 evasion ¹⁷, and, critically, waning vaccine immunity. Waning immunity was evident in both 80 levels of neutralizing antibodies and studies of vaccine effectiveness, including for severe 81 disease in older individuals ^{18,19}. To address the surge in COVID-19 in autumn 2021, third 82 vaccine doses were offered to older ages and at risk individuals, but were not initially offered to 83 healthy younger individuals because VE for severe disease in these age groups remained relatively high ²⁰. However, the potential impacts of offering third doses to all individuals to 84 85 reduce transmission was not considered because of a lack of information on the benefits of indirect protection ²¹. 86

87 Here we estimate the potential impact of third doses of mRNA vaccines on population-88 level transmission of the Delta variant in late 2021 and the number of deaths that could have 89 been averted. We first estimated how VEs and VE₁ change over time due to waning and boosting 90 of immunity. Previous work has demonstrated strong correlations between a surrogate measure of protection, neutralizing antibody titers, and VE for symptomatic and severe disease ^{22–27}, and 91 92 one study used these relationships to examine the impacts of vaccination for averting disease and 93 deaths²⁶. Here, we extend this approach by developing the first relationships, for any pathogen, 94 between neutralizing antibody titers and VEs and VEI, which are required to estimate the impact 95 of vaccination on transmission. We then quantified relationships between neutralizing antibody 96 titers and time since vaccination, and following boosting with a third dose of mRNA vaccines. 97 We integrated these two relationships to estimate the potential impacts of deploying additional

It is made available under a CC-BY-NC-ND 4.0 International license .

- 98 vaccine doses on the reproductive number of the virus, R_t , under multiple scenarios. Finally, we
- 99 estimated the number of Delta infections and deaths that could have been averted in the United
- 100 States in Autumn 2021 by deploying third doses to reduce transmission.
- 101
- 102 Results
- 103 We found very strong relationships between variant- and vaccine-neutralizing antibody
- 104 titer ratios (NATRtot) and VE using 23 estimates of VEs (susceptibility) and 14 estimates of VEI
- 105 (infectiousness) across three variants and four vaccines (Figure 1A,B; Table S1). VEs was higher
- 106 than VE_I across the range of NATR_{tot} observed, but the slope of VE_I was higher (VE increased

107 more rapidly as NATR_{tot} values increased) (Figure 1; Table S1).



It is made available under a CC-BY-NC-ND 4.0 International license .

Fig. 1. Vaccine Effectiveness (VE) plotted against variant- and vaccine-specific neutralizing

110	antibody titer ratios (NATR _{tot}) for (A) susceptibility, VE ₈ , (B) infectiousness, VE _I , and (C)
111	transmission VE _T . Each point (and 95% CI) represents a single empirical estimate of VE
112	for a single vaccine (or infection) & virus variant. Points are jittered slightly along the x-
113	axis to facilitate presentation. Black lines and ribbons in (A) and (B) show the fitted model
114	and 95% CIs. The line and 95% CI ribbon in (C) is estimated from lines in (A) and (B):
115	VE _T = 1-(1-VE _S)*(1-VE _I); see Methods for details.
116	In the eight months after vaccination, neutralizing antibody titers waned approximately 8-
117	fold for vaccine-derived immunity for both BNT162b2 and mRNA-1273 vaccines and 3-fold for
118	infection derived immunity, with most waning occurring in the first 3-5 months (Figure 2A, B;
119	Table S2). Rates of waning were faster for the BNT162b2 vaccine than the mRNA-1273 vaccine
120	and infection-derived immunity (Figure 2B; Table S2). Initial neutralizing antibody titers were
121	highest for vaccination with mRNA-1273, followed by BNT162b2, and lowest following
122	infection (Figure 2A; Table S2).
123	We used the relationships between neutralizing antibody titers and VE (Figure 1) and
124	patterns of waning of antibody titers (Figure 2A, B) to estimate the waning of VEs and VEI over
125	time (Figure 2C, D). As expected from levels of antibody titers, VE_S and VE_I were highest for
126	two-dose vaccination with mRNA-1273, and BNT162b2 vaccines, and then infection-derived
127	immunity (Figure 2C, D). The relatively fast waning rate of neutralizing antibodies for the
128	BNT162b2 vaccine suggests that VE for this vaccine was initially much higher than infection-
129	derived immunity, but the two were similar after 3-4 months (Figure 2C, D). VE for the mRNA-
130	1273 vaccine remained higher than both the BNT162b2 vaccine and previous infection as

131 protection waned (Figure 2C, D).

109

It is made available under a CC-BY-NC-ND 4.0 International license .

132	A third dose of the BNT162b2 vaccine boosted antibody titers 26-fold relative to levels
133	after 8 months of waning, or $25.9/8.1 = 3.2$ -fold higher than one week after dose two ²⁸ . A third
134	dose of the mRNA-1273 vaccine boosted antibody titers 13-fold relative to 8-month waned
135	levels, or 1.5-fold higher than shortly after the second dose. The fitted relationship between VEs
136	and neutralizing antibody titer ratios (Figure 1) suggested that third doses of the mRNA vaccines
137	would increase VEs 1.6-1.8-fold from waned values of 47-54% to boosted values of 85-86% and
138	would boost VE _I 3-4-fold from 16-22% to 65-68% (Table S3; Figure 2C,D; compare blue and
139	purple points in upper right of panels to lines of the same color below). Combined, boosting
140	waned individuals with a third vaccine dose increased VE for transmission ($VE_T = 1-(1-VE_S)^*$
141	VE _I)) from 55.4% to 95.4% for BNT162b2 and from 64.3% to 94.5% for mRNA-1273. In doing
142	so, boosting reduced the risk of transmission (1-VE _T) by ~10-fold or 89.7% for BNT162b2 and
143	~7-fold or 84.5% for mRNA-1273 vaccinated individuals compared to waned immunity.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 2. Waning of neutralizing antibody titers and VE for susceptibility (VE_S) and infectiousness (VE_I) over time and following boosting with a third dose. Lines show fitted models and ribbons show \pm 1 SE (Table S1). A) Neutralizing antibody titers relative to convalescent sera with wild-type (WT) virus, adjusted for the 2.2-fold lower neutralization titers with the Delta variant relative to wild-type virus. B) The same data as in panel A but rescaled relative to the initial peak value (i.e. all lines start at a value of 1) to show relative

It is made available under a CC-BY-NC-ND 4.0 International license .

rates of waning and levels of stabilization (Table S1). C) VE for susceptibility (VE_S) over
time using the patterns of waning in Panel A and the relationships between antibody titers
and VE for susceptibility (Figure 1A). D) VE for infectiousness (VE_I) over time using the
patterns of waning in Panel A and the relationships between antibody titers and VE for
infectiousness (Figure 1B). Points in the upper righthand corner of panels C and D,
indicated by the black arrows, show the effect of third doses in boosting VE for the
BNT162b2 and mRNA-1273 vaccines.

158 Next, we examined the impacts of third doses on population-level transmission in the United States via reductions in the reproductive rate of the pathogen, Rt. On September 1, 2021, 159 160 the average time since vaccination for vaccinated individuals (53.2% of the population) was 4 161 months (118.3 days) (Figure S1) resulting in average antibody titers waning to less than 22% of 162 peak values. If all doubly vaccinated individuals in the USA received a third dose of an mRNA 163 vaccine that took effect on 1 September 2021 this would have reduced R_t by 18.4% (95% CI: 164 15.0% to 21.8%) from 1.17 to 0.96 (Figure 3D). This would have stopped the strong surge in 165 cases, hospitalizations, and deaths that occurred over the next few months, assuming contact 166 rates and other behaviors didn't change following boosting (see Methods for further details). 167 Notably, using the same number of doses to doubly vaccinate unvaccinated individuals 168 (assuming they were willing to be vaccinated) rather than boost previously vaccinated 169 individuals would have been similarly effective in reducing transmission (Rt would decrease 170 from 1.17 to 0.94 versus 1.17 to 0.96 for using doses for boosting vaccinated individuals) (Figure 3D, compare right end of red line to red point labeled " $R_0 = 3.2, 79.8\%$ vacc., no 3rd doses" on 171 172 left side). We also explored several other scenarios with varying vaccination and infection rates 173 and contact rates, which showed that the percent reduction in Rt was driven primarily by the

It is made available under a CC-BY-NC-ND 4.0 International license .

- 174 fraction of the population vaccinated, which determined the potential boosting fraction
- 175 (Supplemental Results Text, Figure S2).



177Figure 3. United States population vaccination and infection history over time, population-178level vaccine effectiveness against susceptibility (VEs) and infectiousness (VEI) over time,179and the relationship between the pathogen effective reproductive number, R_t and third180dose coverage, as of 1 September, 2021. A) Fraction of the US population that had received

It is made available under a CC-BY-NC-ND 4.0 International license .

181	their primary vaccination series but had not been infected (Frac. Vacc.), had been infected
182	but not vaccinated (Frac. Inf.), had been both vaccinated and infected (Frac. Hybrid), or
183	had received their third-dose booster (Frac. Boost). B) and C) Lines ± 1 SE show
184	population-level VE against susceptibility (B) and infectiousness (C) over time for three
185	subpopulations (vaccinated with their primary series, previously infected, and both
186	vaccinated and previously infected [hybrid]) and the entire population in the US ("Total")
187	which is a mixture of the five subpopulations, as shown in panel (A). Rectangles above
188	panels (A-C) show which variant was dominant during the period (frequency \geq 50%). D)
189	Line \pm 1 SE shows R_t plotted against the fraction of vaccinated individuals receiving third
190	dose boosters for the United States with $R_0=3.2$, 53.2% vaccinated, and 67.4% previously
191	infected as of September 1, 2021 (see Methods for additional details). The single red point
192	shows the impact of using all third doses from the right end of the red line to doubly-
193	vaccinate unvaccinated individuals, which would bring the vaccination coverage from
194	53.2% to 79.8%. The dashed horizontal line shows the threshold reproductive number R_t =
195	1, separating growing from shrinking epidemics.
196	Between June 2021, when the Delta variant emerged, and January 2022, the Delta variant

caused an estimated 273,801 deaths ¹⁴, with the average number of estimated daily cases
sometimes exceeding 200,000 (Figure S3), and reported deaths sometimes exceeding 2,000/day
(Figure 4). However, during this period the estimated Rt for the US population mostly fluctuated
between 0.9 and 1.1 (Figure S3), suggesting that many thousands of deaths could have been
prevented if Rt could have been reduced, even marginally. As we just illustrated, boosting the

202 53.2% of the population that had been vaccinated with a third dose by 1 September, 2021 would

 $203 \qquad \text{have reduced } R_t \text{ by } 18.4\% \text{ (Figure 3D, red line). This would have reduced the number of Delta}$

It is made available under a CC-BY-NC-ND 4.0 International license .

- 204 deaths by 111,525 (95% CI: 103,819 to 116,641) (Figure 4E, blue shaded region) by averting
- 205 37,174,963 infections (95% CI: 34,606,246 38,880,500) (Figure 4A, orange shaded region).
- 206 Boosting with third doses could have averted 629.5 (95% CI: 586.0 to 658.3) deaths per million
- 207 vaccine doses administered due to effects on transmission alone.



208

209 Figure 4. Estimated daily infections (A-D) and reported or estimated deaths (E-H) with and 210 without third dose boosting plotted against time in the United States when the Delta SARS-211 CoV-2 variant was dominant. Black lines in the left panels show the estimated number of 212 infections each day, calculated by deconvolution using the observed daily deaths (dark blue 213 lines in right panels) and the delays between infection and death, and using and an infection fatality ratio (IFR) of 0.003²⁹. Deaths from the Delta variant were estimated using 214 215 reported deaths and variant fractions based on sequencing data (see Methods). Red lines in 216 left panels show the estimated number of infections with third dose boosting, and light blue 217 lines show the number of deaths resulting from these infections with the timing estimated

It is made available under a CC-BY-NC-ND 4.0 International license .

218	by reconvolution given the same distributions. The shaded regions show the averted
219	infections (orange) and deaths (blue) if all eligible vaccinees received third doses that took
220	full effect on Sept. 1, Oct. 1, Nov. 1, or Dec. 1 as indicated on the panel title with the
221	reduction in R_t for these dates shown in Figure S2.
222	Boosting populations after Sept. 1 would have resulted in greater reductions in R_t as
223	immunity in the vaccinated group continued to wane but would avert fewer deaths caused by the
224	Delta variant. Boosting on October 1, November 1, or December 1 would have reduced R_t by
225	29.7%, 31.2%, and 30.0%, respectively (Figure S2), but would avert 73,574 (95% CI: 69,253 $-$
226	75,962), 36,424 (95% CI: 33,085 – 38,350) and 5,970 (95% CI: 5,039 – 6,617) Delta deaths
227	(Figure 4; Table S5).

228

229 **Discussion**

230 The indirect effects of vaccination in reducing disease by reducing transmission (via 231 reduced susceptibility or infectiousness) were rarely considered at any stage of COVID-19 232 vaccination programs, including initial trial design, initial vaccination, and subsequent boosting. 233 We found that boosting population immunity with third vaccine doses could have substantially 234 reduced transmission of the most deadly SARS-CoV-2 variant, Delta, stopped surges, and 235 averted huge numbers of deaths in many populations, including more than 100,000 in the US. 236 We estimated that 629 deaths could have been averted per million vaccine doses which is similar 237 to or higher than the direct effects of COVID-19 vaccination in other studies (93 to 836 deaths per million doses administered ^{30–33}). However, many countries initially offered third doses only 238 239 to protect at-risk individuals and only later offered third doses to the general population 20 . 240 Likely as a result, third dose uptake by the general population in most countries was low. It may

It is made available under a CC-BY-NC-ND 4.0 International license .

have been higher if the third dose boosters were immediately and strongly recommended, or
 mandated for the whole population ³⁴.

The approach we developed here provides an empirical framework for estimating the 243 effect of vaccination on transmission in a dynamic immune landscape. The key components are 244 245 the temporal dynamics of a surrogate of protection neutralizing antibody titers and relationships 246 between neutralizing antibody titers and the two components of transmission: susceptibility and 247 infectiousness. Previous studies have shown that neutralizing antibody titers were strongly 248 correlated with VE for symptomatic disease and severe disease ^{22–24,26,27}. Here, we significantly advanced this approach by showing that antibody titers were also strongly correlated with VEs 249 250 and VE_I. This advance is critical for building accurate mathematical models of SARS-CoV-2 251 transmission as immunity wanes and is boosted with additional vaccine doses or infection. 252 Previous models have assumed VE for transmission was the same as VE for symptomatic 253 disease²⁶, which underestimates susceptibility (the relative risk of infection) and underestimates 254 transmission (Figure S4). A similar empirical framework for estimating the effect of vaccination 255 on transmission could be developed for other pathogens, such as influenza virus, but it would 256 require a surrogate of protection³⁵ and multiple estimates of vaccine efficacy for susceptibility and infectiousness in population with different levels of immunity. 257

We found that VEs and VE_I declined rapidly in the first 3-5 months post-vaccination in BNT162b2 recipients and plateaued after ~6 months, with slower, waning in mRNA-1273 recipients, which may or may not be related to long lasting plasma cells ^{36,37}. These rates of waning suggest that vaccinating individuals multiple times per year would have substantially increased VE for transmission against the Delta variant, and would likely increase VE for transmission for the currently circulating SARS-CoV-2 variants as well. Given the summer

It is made available under a CC-BY-NC-ND 4.0 International license .

surges of COVID-19 hospitalizations that now appear to be a repeatable phenomenon,

recommending two vaccine doses per year for COVID-19, especially in sensitive settings such as
skilled nursing facilities, could provide substantial benefits.

267 We found third vaccine doses could have reduced Delta deaths dramatically, but the 268 impact depended on the timing when doses were administered. Rolling out third doses by 269 September 1 would have averted an additional 37,951 Delta deaths in the US compared to 270 waiting until October 1, which emphasizes the timeliness of vaccinations. Two related factors 271 made a September 1 rollout especially impactful. First, infections were near their peak in 272 September. Second, Rt was below 1.03 from September 1 until late November when the Omicron 273 variant began to invade. The potential reduction in Rt due to third doses (18.4%) was sufficient 274 to reduce Rt well below 1 which would have driven Delta infections and deaths down rapidly 275 (Figure 4). Administering third doses later would have averted fewer deaths caused by the Delta 276 variant (but may have averted additional infections and deaths caused by the Omicron variant).

277 Our study has several limitations. First, our analyses use population averages for 278 estimates of VE_s and VE_l and ignore age-specific variation among individuals, as well as other 279 factors. Age-specific patterns of contact, disease severity, and immunity can play a key role in 280 shaping epidemics ³⁸. We also assumed well-mixed populations in calculating reductions in the 281 reproductive number Rt. A targeted vaccination approach would be more effective than that 282 outlined here if highly connected individuals could be targeted for third doses ³⁹. Third, our 283 calculations for the reductions in Rt with third doses were based on neutralizing antibody titers 284 one month after the administration of a third dose. Neutralizing antibody titers also decay 285 following third doses, but the decay rate is much slower than after second doses ⁴⁰, suggesting 286 that substantial reductions in Rt from third doses would persist for many months, as we assumed

It is made available under a CC-BY-NC-ND 4.0 International license .

287 here. Fourth, our analyses were focused on population characteristics in the US in late 2021 and 288 vaccine effectiveness against the Delta variant because data were available for quantifying 289 immunity in populations at this time. The current impact of vaccine doses on transmission of 290 SARS-CoV-2 is more difficult to quantify with currently available data, due to a more complex 291 immune landscape, with most people having been infected several times with multiple virus 292 variants and vaccinated with multiple vaccine types, and the variant composition of SARS-CoV-293 2 viruses is sometimes diverse and changes frequently. Determining the current benefit of 294 vaccination for reducing transmission would require estimates of the distribution of neutralizing antibody titers against currently circulating viruses in target populations, and measuring 295 296 increases in antibody titers following vaccination. Finally, quantifying the impact of vaccination 297 in reducing deaths due to reduced transmission does not take into account additional benefits of 298 reduced infections including reduced absenteeism from work and school and reduced cases of 299 long COVID. The total benefits of reduced transmission may outweigh the costs of administering 300 additional vaccine doses in many populations.

In summary, we showed that the indirect benefits of vaccination in reducing transmission can lead to a huge number of deaths averted. In addition, reductions in transmission increase health equity by reducing infection in individuals that lack access to vaccination. Quantifying vaccine impacts on transmission should be an integral part of developing new vaccines, and estimates of reductions in transmission should be used for planning vaccination strategies, including vaccine selection, targeting, and vaccination schedules.

307

308 Methods

309 *Relative neutralizing antibody titers by variant, vaccine dose and with waning*

It is made available under a CC-BY-NC-ND 4.0 International license .

310	We collected data on neutralizing antibody titers from the literature and estimated the
311	total neutralizing antibody titer ratio (NATR $_{tot}$) for each vaccine, virus variant, and immune
312	status ²⁴ . NATR _{tot} is the ratio of neutralizing antibody titer for a given vaccine, variant and
313	immune status, relative to the neutralizing antibody titer of convalescent sera after infection with
314	the original wild-type virus ^{24,27} . For example, two weeks after a second dose of the BNT162b2
315	vaccine $NATR_{tot}$ for the Delta variant is 1.08, because vaccination with BNT162b2 results in
316	neutralizing antibody titers 2.37-fold higher than infection ^{24,27} , and neutralizing antibody titers
317	against the Delta variant are 2.20-fold lower than against wild-type virus; $2.37*(1/2.2) = 1.08^{24}$.
318	We also collected data from studies measuring neutralizing antibody titers over time in sets of
319	individuals following infection or vaccination to quantify waning of neutralizing antibody titers,
320	as well as increases in antibody titers following boosting with third doses ^{28,41,42} . We then fit
321	models to the decay in antibody titers over time following vaccination with two mRNA vaccines
322	(BNT162b2 and mRNA-1273), and infection (Table S1). We assumed antibody titers from
323	hybrid immunity (infection followed by vaccination) waned at the same rate as following BNT
324	162b2 vaccination based on a study that measured both ⁴² .

325

326 *VE for susceptibility and infectiousness*

We collected VE estimates for susceptibility and infectiousness for SARS-CoV-2 from the literature, including a systematic living review ⁴³, and categorized each study by vaccine, time since vaccination, and variant type (wild-type/D614G, Alpha, Delta). We excluded estimates where the virus variant could not be determined. For estimates of VEs, we only included studies where the endpoint was "all infections" (often measured using frequent testing or serology) and excluded studies where the endpoint was "any infection" because "any

It is made available under a CC-BY-NC-ND 4.0 International license .

infection" studies do not capture all infections and include an unknown fraction of asymptomatic
infections. Studies of VE_I, or transmission given infection, usually compared secondary attack
rates in households by vaccination status of the index case.

336 To fit a relationship between VE and NATR, we needed estimates of the number of 337 infections in the vaccine and control groups. However, most studies did not report the number of 338 infections; however, all reported a VE and 95% CI. We estimated the effective number of 339 infected individuals in the control group (I_c) and the effective number of infected individuals in 340 the vaccine group (I_v) for each study by determining the number of each needed to match the 341 mean and 95% CI given in a study. We held the effective number of individuals in the control 342 group (N_c) and vaccine group (N_v) constant at 1,000,000 because the 95% CI was invariant to 343 variation in these values for observed incidence values. We used a maximum value of 1000 infections in the control group (I_c) to reduce the undue leverage of some very large studies ⁴⁴. 344

345

346 Relationships between VE and neutralizing antibody titers by vaccine and variant

We modeled the relationship between VE and total neutralizing antibody titer ratios
 (NATR_{tot}) using ²⁴:

349
$$VE = 1 - \frac{1}{1 + e^{-(c_0 + c_1 \log_2(NATR_{tot}))}}$$
 (1)

We estimated the coefficients c₀ and c₁ separately for the two endpoints, susceptibility and infectiousness, by maximizing the likelihood of observing the data underlying the VE estimates: the number of infections in the control group, I_c, and vaccine group, I_v, for each study. The likelihood was the product of two binomial distributions with N_c and N_v individuals:

354
$$L(N_c, I_c, N_v, I_v | NATR_{tot}, b_s, c_0, c_1) = Bi(N_c, I_c, b_s) * Bi(N_v, I_v, b_s * VE)$$
 (2)

It is made available under a CC-BY-NC-ND 4.0 International license .

355	Here b_s is the baseline risk for the study period, which is the fraction of control individuals
356	infected during the study. We maximized the likelihood across all studies which was the product
357	of the likelihoods of the individual studies. We used the fitted relationships for the two
358	endpoints, susceptibility and infectiousness, between VE and neutralizing antibody titer ratios,
359	$NATR_{tot}$ (eq 1) to estimate VE for populations based on the estimated $NATR_{tot}$ given the timing
360	of vaccination and infection and estimated rates of waning as described above. Finally we
361	calculated the VE for transmission, $VE_T = 1-(1-VE_S)^*(1-VE_I)$. We calculated 95% CIs for VE_T
362	using independent bootstrap samples from the VEs and VEI estimates and 95% CIs.
363	

364 Vaccine effectiveness over time

365 We estimated VEs and VEI in the US for each day from January 1, 2021 to December 13, 366 2021 for three subpopulations: previously infected and unvaccinated, twice vaccinated and no 367 previous infection, and twice vaccinated and previously infected (hybrid immunity), the timing 368 of prior infections and vaccinations (Figure S1), and the relationships between neutralizing 369 antibody titers and VE_s and VE_I. We estimated the timing of infections using reported deaths ⁴⁸ 370 and deconvolution, using the distributions for the delays between infection and death (i.e. 371 infection to shedding, shedding to symptom onset, symptom onset to hospitalization, and hospitalization to death) (Table S6) using the deconvolve package in R⁴⁵. For each day, we 372 373 estimated VEs and VE_I in each subpopulation against each circulating variant based on the 374 timing of infections and vaccinations, accounting for the waning that occurred in each 375 subpopulation on that date using the fitted model for the relationship between neutralizing antibodies and time since infection and vaccination. We used sequencing data from GISAID ^{29,46} 376 377 (offset by 9 days to account for the average delay between infection and reporting date) in the

It is made available under a CC-BY-NC-ND 4.0 International license .

378 US to get a variant-averaged estimate of VEs and VEI in each subpopulation for each day using a 379 weighted mean where weights were the observed variant frequency each day. We then estimated 380 a population-wide VE for each day using estimates for the fraction of the population in five 381 subpopulations: fully susceptible, third-dose boosted, and the three subpopulations described 382 above.

383

384 The impact of third doses on the reproductive number, R_t

385 We used patterns of waning and boosting of neutralizing antibody titers to estimate the 386 impact of providing additional doses of mRNA vaccines to increasing fractions of vaccinated 387 individuals in the USA and other populations on the reproductive number, R_t , of the Delta variant 388 of SARS-CoV-2, at four time points in autumn 2021; Sept 1, Oct 1, Nov 1, and Dec 1 (Table 389 S4). R_t is the average number of secondary cases that each case infects and is equal to the basic 390 reproductive number for a pathogen in a fully susceptible population, R_0 , multiplied by the 391 fraction of the population that is susceptible (i.e. not immune from vaccination or previous 392 infection).

We examined the effect of boosting vaccinated individuals with a third dose on Rt by considering five scenarios which were combinations of vaccination, previous infection and contact rates that span the range of circumstances in many countries in late 2021. The five scenarios (with fraction vaccinated and previously infected shown for 1 September 2021) and rationale were (Table S4):

It is made available under a CC-BY-NC-ND 4.0 International license .

398	1)	US/D (United States with distancing): $R_0 = 3.2, 53.2.\%$ vaccinated, 67.4% previously
399		infected: approximated fraction of US population previously infected with contact rates
400		similar to summer-fall 2021
401	2)	CA/D (California, USA, with distancing): $R_0 = 3.2, 58.7\%$ vaccinated, 59.8% previously
402		infected: approximated some populations with higher vaccination and lower fraction
403		infected than scenario (1) (e.g. California)
404	3)	NZ/ND (New Zealand, no distancing): R ₀ =7.0, 24.3% vaccinated, 0.2% previously
405		infected: approximated countries with high vaccination rates that effectively suppressed
406		transmission and had reduced contact rates when cases were detected (e.g. New Zealand,
407		Australia, Hong Kong, etc.)
408	4)	US/ND (United States, no distancing): $R_0 = 7.0$, 53.2% vaccinated, 67.4% previously
409		infected: a scenario to compare to scenario (1) to determine if boosting could limit
410		transmission if behavior returned to pre-pandemic levels
411	5)	US/ND-100 (United States, no distancing): R0 = 7.0, 100% vaccinated, 67.4% previously
412		infected: a hypothetical optimistic scenario to compare to scenario (1) to determine if
413		vaccination with or without boosting could limit transmission if behavior returned to pre-
414		pandemic levels

We estimated the fraction of the population that was susceptible using data on the fraction of the population that had been vaccinated or infected or both. We first split each population into three groups based on vaccination status: fraction unvaccinated, f_U , fraction vaccinated, f_V , with two doses of either BNT162b2 or mRNA-1273, and fraction boosted with a third dose of the same vaccine used for the primary series, f_B ($f_U+f_V+f_B=1$). We calculated the fraction of people in the USA receiving BNT162b2 and mRNA-1273 from vaccination records ⁴⁷. We estimated the

It is made available under a CC-BY-NC-ND 4.0 International license .

421 timing of infections using deconvolution of deaths as described above and calculated the number 422 of infections by dividing deaths by an estimate of the infection fatality ratio (IFR) across of 2020-21 of 0.003²⁹; the results were not sensitive to moderate variation in this estimate. We also 423 examined estimating infections using cases and an infection/case ratio of 4.0⁴⁸ which produced a 424 425 lower estimate of total infections, and the reduction in R_t with third dose boosting and deaths 426 averted were very similar to the death-deconvolution and IFR method. We estimated the fraction 427 of unvaccinated or vaccinated individuals that had been previously infected using the ratios of cases in these two groups over time in the USA ⁴⁹ (Figure S5). We used vaccination and 428 429 infection data to calculate the fraction of people previously infected among unvaccinated, f_{PU} , 430 and vaccinated, f_{PV} individuals (Table S4). We used rates of waning of antibody titers and data on the timing of vaccination and infection from the USA and New Zealand ⁴⁷ for US and New 431 432 Zealand scenarios, respectively, to estimate the distribution of NATR_{tot} in populations for the 433 four time points in autumn 2021. We used the distributions of NATR_{tot} to estimate the relative 434 susceptibility, 1-VEs, (Figure 1A) and relative infectiousness, 1-VE_I, (Figure 1B) for the 435 population in each of four groups: unvaccinated and previously infected (VE_{SP} and VE_{IP}), 436 vaccinated twice and no previous infection (VEsv and VE_{IV}), vaccinated three times or boosted 437 (VE_{SB} and VE_{IB}), and vaccinated and infected or hybrid immunity (VE_{SH} and VE_{IH}), all with 438 appropriate adjustments for waning antibody titers (see below). We used these estimates of VE 439 to calculate Rt for populations composed of different fractions of five groups: never infected 440 unvaccinated $(1-f_{PU})f_{U}$, previously infected unvaccinated $f_{P}f_{U}$, previously uninfected vaccinated 441 with two doses (1-f_{PV})f_V, previously infected and vaccinated with two doses f_{PV}f_V, and boosted 442 with a third dose, regardless of previous infection, f_B:

It is made available under a CC-BY-NC-ND 4.0 International license .

443
$$R_t = R_0 [(1-f_{PU})f_U + f_{PU}f_U(1-VE_{SP})(1-VE_{IP}) + (1-f_{PV})f_V(1-VE_{SV})(1-VE_{IV}) + (f_{PV}f_V)(1-VE_{SH})(1-VE_{IH}) + (f_B)(1-VE_{SB})(1-VE_{IB})]$$
 (3)

445 Note that in equation (3) the VE values for each population are integrated across the
446 distribution of NATR_{tot} values for that group, and the distribution of NATR_{tot} values in each

447 group reflects the timing of vaccination and infection on a daily timestep.

448 We used the scenario estimates of the fraction of population with different types of immunity

449 (with timing matched to vaccination and infection and waning as described above) for

450 susceptibility and infectiousness to estimate values of Rt under each scenario at the four time

451 points in autumn 2021 (Sept. 1, Oct. 1, Nov. 1, and Dec. 1; Table S4). We calculated 95% CIs

452 for predicted values of Rt that incorporated uncertainty in the relationship between time since

453 vaccination or infection and NATR_{istatus}, uncertainty in the relationships between neutralizing

antibody titers and VEs and VEI, as well as uncertainty in NATR_{vac} and NATR_{var} (Figures 1 and

455 S2).

456

457 The impact of third doses on infections and deaths caused by the Delta variant

We estimated the timing of the infections that gave rise to observed deaths and total infections in the United States in autumn 2021 using deconvolution as described above. We used SARS-CoV-2 sequencing data ^{29,46} to estimate the daily fraction of all infections that were caused by the Delta variant. We estimated the reduction in Delta infections if third-dose boosters were given to all fully vaccinated individuals at four time points in autumn 2021. We assumed the additional doses would take full effect simultaneously on Sept. 1, Oct. 1, Nov. 1, or Dec. 1. We estimated the number of Delta infections that would have occurred if third doses had been

It is made available under a CC-BY-NC-ND 4.0 International license .

465	deployed by multiplying the number of estimated infections on each day by the reduction in the
466	daily R_t due to third doses (e.g. 0.812 if R_t was reduced by 18.8%), raised to the power of the
467	number of generations of infections (generation time 3.8d ⁵⁰) since Sept 1 (or Oct. 1, Nov. 1 or
468	Dec. 1). The calculated reduction in R_t was the difference between the number of actual third-
469	doses given, and the number of doses deployed in the scenario. We estimated the number of
470	deaths that would have been averted in each scenario by re-convoluting the reduced infections,
471	multiplied by the IFR, using the delays described previously. We used uncertainty associated
472	with our R_t estimates to calculate 95% CIs in the number of deaths averted.
473	
474	Author Contributors
475	BJG and AMK conceived the study, performed the analyses and wrote the paper.
476	Declaration of competing interests
477	All authors declare no competing interests.
478	Data sharing
479	All data used in the paper are contained in the supplemental material.
480	R Code and data files to replicate the figures and analyses of this paper are available:
481	https://github.com/marmkilpatrick/Vaccine-boosters
482	Upon publication, R Code will be uploaded to Zenodo and data files will be archived with
483	Dryad.
484	Acknowledgements
485	Funding

It is made available under a CC-BY-NC-ND 4.0 International license .

- 486 We received funding from the National Science Foundation (DEB- 1911853, 1115895, and
- 487 1717498) and the California Department of Health.

- 489 **References**
- 490 1 Allen A. Vaccine—the controversial story of medicine's greatest lifesaver. New York, NY:
 491 W.W. Norton & Co., 2007.
- 492 2 Minor PD. Live attenuated vaccines: Historical successes and current challenges. *Virology*493 2015; 479–480: 379–92.
- 494 3 Greenwood B. The contribution of vaccination to global health: past, present and future. *Phil*495 *Trans R Soc B* 2014; **369**: 20130433.
- 4 Hinman AR, Orenstein WA, Schuchat A. Vaccine-preventable diseases, immunizations, and
 MMWR--1961-2011. *MMWR Suppl* 2011; 60: 49–57.
- 498 5 Roush SW. Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable
 499 Diseases in the United States. *JAMA* 2007; **298**: 2155.
- 6 Hudgens MG, Gilbert PB, Self SG. Endpoints in vaccine trials. *Stat Methods Med Res* 2004;
 13: 89–114.
- 502 7 Li X, Mukandavire C, Cucunubá ZM, *et al.* Estimating the health impact of vaccination
 503 against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a
 504 modelling study. *The Lancet* 2021; **397**: 398–408.
- 8 COVID-19: Developing Drugs and Biological Products for Treatment or Prevention. 2023.
 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19 developing-drugs-and-biological-products-treatment-or-prevention.
- 508 9 CDC. Child and Adolescent Immunization Schedule by Age. 2023.
 509 https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html.
- 510 10CDC. Direct and indirect effects of routine vaccination of children with 7-valent
- 511 pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United
- 512 States, 1998-2003. 2005. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5436a1.htm.
- 513 11 Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. 1985.
- 514 12Medlock J, Galvani AP. Optimizing Influenza Vaccine Distribution. *Science* 2009; 325:
 515 1705–8.
- 516 13Marmot M. Achieving health equity: from root causes to fair outcomes. *The Lancet* 2007;
 517 **370**: 1153–63.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 518 14 Walker J, Grubaugh ND, Gonsalves G, Pitzer V, Rizvi Z. One Million and Counting:
- 519 Estimates of Deaths in the United States from Ancestral SARS-CoV-2 and Variants. *medRxiv* 520 2022; : 2022.05.31.22275835.
- 521 15Campbell F, Archer B, Laurenson-Schafer H, *et al.* Increased transmissibility and global
 522 spread of SARS-CoV-2 variants of concern as at June 2021. *Eurosurveillance* 2021; 26.
- 523 DOI:10.2807/1560-7917.ES.2021.26.24.2100509.
- 16Elliott P, Haw D, Wang H, *et al.* Exponential growth, high prevalence of SARS-CoV-2, and
 vaccine effectiveness associated with the Delta variant. *Science* 2021; **374**: eabl9551.
- 17 Planas D, Veyer D, Baidaliuk A, *et al.* Reduced sensitivity of SARS-CoV-2 variant Delta to
 antibody neutralization. *Nature* 2021; **596**: 276–80.
- 528 18Lustig Y, Zuckerman N, Nemet I, et al. Neutralising capacity against Delta (B.1.617.2) and
- 529 other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in
- health care workers, Israel. *Eurosurveillance* 2021; **26**. DOI:10.2807/1560-
- 531 7917.ES.2021.26.26.2100557.
- 19Wu K, Werner AP, Moliva JI, *et al.* mRNA-1273 vaccine induces neutralizing antibodies
 against spike mutants from global SARS-CoV-2 variants. *bioRxiv* 2021; published online Jan
 25. DOI:10.1101/2021.01.25.427948.
- 20Bar-On YM, Goldberg Y, Mandel M, *et al.* Protection Across Age Groups of BNT162b2
 Vaccine Booster against Covid-19. *medRxiv* 2021; published online Oct 7.
 DOI:10.1101/2021.10.07.21264626.
- 538 21 Krause PR, Fleming TR, Peto R, *et al.* Considerations in boosting COVID-19 vaccine immune
 539 responses. *The Lancet* 2021; **398**: 1377–80.
- 540 22Cromer D, Steain M, Reynaldi A, *et al.* Neutralising antibody titres as predictors of protection
 541 against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *The Lancet*542 *Microbe* 2022; 3: e52–61.
- 543 23Cromer D, Steain M, Reynaldi A, *et al.* Predicting vaccine effectiveness against severe
 544 COVID-19 over time and against variants: a meta-analysis. *Nat Commun* 2023; 14: 1633.
- 545 24Gardner BJ, Kilpatrick AM. Predicting Vaccine Effectiveness for Hospitalization and
 546 Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers.
 547 *Viruses* 2024; 16. DOI:10.3390/v16030479.
- 548 25 Hogan AB, Doohan P, Wu SL, *et al.* Estimating long-term vaccine effectiveness against
 549 SARS-CoV-2 variants: a model-based approach. *Nat Commun* 2023; 14: 4325.
- 26Hogan AB, Wu SL, Toor J, *et al.* Long-term vaccination strategies to mitigate the impact of
 SARS-CoV-2 transmission: A modelling study. *PLoS Med* 2023; 20: e1004195.

It is made available under a CC-BY-NC-ND 4.0 International license .

552 27 Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of 553 immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021; 27: 1205-11. 554 28Falsey AR, Frenck RW, Walsh EE, et al. SARS-CoV-2 Neutralization with BNT162b2 555 Vaccine Dose 3. N Engl J Med 2021; 385: 1627-9. 556 29 Kilpatrick AM. Ecological and Evolutionary Insights About Emerging Infectious Diseases 557 from the COVID-19 Pandemic. Annu Rev Ecol Evol Syst 2023; 54: 171-93. 558 30 Kayano T, Sasanami M, Kobayashi T, et al. Number of averted COVID-19 cases and deaths 559 attributable to reduced risk in vaccinated individuals in Japan. The Lancet Regional Health -560 Western Pacific 2022; 28: 100571. 561 31 Haas EJ, McLaughlin JM, Khan F, et al. Infections, hospitalisations, and deaths averted via a 562 nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 563 vaccine in Israel: a retrospective surveillance study. The Lancet Infectious Diseases 2022; 22: 564 357-66. 565 32 Santos CVBD, Noronha TGD, Werneck GL, Struchiner CJ, Villela DAM. Estimated COVID-566 19 severe cases and deaths averted in the first year of the vaccination campaign in Brazil: a 567 retrospective observational study. The Lancet Regional Health - Americas 2023; 17: 100418. 568 33 Mendes D, Chapman R, Gal P, et al. Public health impact of booster vaccination against 569 COVID-19 in the UK during Delta variant dominance in autumn 2021. Journal of Medical 570 Economics 2022; 25: 1039–50. 571 34 Mello MM, Opel DJ, Benjamin RM, et al. Effectiveness of vaccination mandates in 572 improving uptake of COVID-19 vaccines in the USA. The Lancet 2022; 400: 535-8. 573 35 Ward BJ, Pillet S, Charland N, Trepanier S, Couillard J, Landry N. The establishment of 574 surrogates and correlates of protection: Useful tools for the licensure of effective influenza 575 vaccines? Human Vaccines & Immunotherapeutics 2018; 14: 647–56. 576 36Nguyen DC, Hentenaar IT, Morrison-Porter A, et al. SARS-CoV-2-specific plasma cells are 577 not durably established in the bone marrow long-lived compartment after mRNA vaccination. 578 Nat Med 2024; published online Sept 27. DOI:10.1038/s41591-024-03278-y. 579 37 Schulz AR, Fiebig L, Hirseland H, et al. SARS-CoV-2 specific plasma cells acquire long-580 lived phenotypes in human bone marrow. eBioMedicine 2023; 95: 104735. 581 38 Yuan H-Y, Baguelin M, Kwok KO, Arinaminpathy N, Van Leeuwen E, Riley S. The impact 582 of stratified immunity on the transmission dynamics of influenza. *Epidemics* 2017; 20: 84–93. 583 39 Firth JA, Hellewell J, Klepac P, Kissler S, Kucharski AJ, Spurgin LG. Using a real-world 584 network to model localized COVID-19 control strategies. Nat Med 2020; 26: 1616–22.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 585 40Gilboa M, Regev-Yochay G, Mandelboim M, et al. Durability of Immune Response After
- 586 COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection. JAMA
 587 Netw Open 2022; 5: e2231778.
- 41 Chu L, Vrbicky K, Montefiori D, *et al.* Immune response to SARS-CoV-2 after a booster of
 mRNA-1273: an open-label phase 2 trial. *Nat Med* 2022; 28: 1042–9.
- 42Goel RR, Painter MM, Apostolidis SA, *et al.* mRNA vaccines induce durable immune
 memory to SARS-CoV-2 and variants of concern. *Science* 2021; **374**: abm0829.
- 43 Higdon MM, Wahl B, Jones CB, *et al.* A Systematic Review of Coronavirus Disease 2019
 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus
 2 Infection and Disease. *Open Forum Infectious Diseases* 2022; 9: ofac138.
- 44Lewnard JA, Patel MM, Jewell NP, *et al.* Theoretical Framework for Retrospective Studies of
 the Effectiveness of SARS-CoV-2 Vaccines. *Epidemiology* 2021; 32: 508–17.

45Lewnard JA, Liu VX, Jackson ML, *et al.* Incidence, clinical outcomes, and transmission
dynamics of hospitalized 2019 coronavirus disease among 9,596,321 individuals residing in
California and Washington, United States: a prospective cohort study. 2020; published online
April 16. DOI:10.1101/2020.04.12.20062943.

- 46Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data from vision to
 reality. *Eurosurveillance* 2017; 22. DOI:10.2807/1560-7917.ES.2017.22.13.30494.
- 47 Mathieu E, Ritchie H, Rodés-Guirao L, *et al.* Coronavirus Pandemic (COVID-19). Our World
 in Data. 2020.
- 48CDC. Estimated COVID-19 Burden. 2021. https://www.cdc.gov/coronavirus/2019 ncov/cases-updates/burden.html.
- 607 49COVID Data Tracker. CDC. 2021. https://covid.cdc.gov/covid-data-tracker/.
- 50Park SW, Sun K, Abbott S, *et al.* Inferring the differences in incubation-period and
- 609 generation-interval distributions of the Delta and Omicron variants of SARS-CoV-2.
- 610 *Proceedings of the National Academy of Sciences* 2023; **120**: e2221887120.